Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Discontinuing antidepressants: Pearls and pitfalls

Samantha J. Zwiebel, MD and Adele C. Viguera, MD
Cleveland Clinic Journal of Medicine January 2022, 89 (1) 18-26; DOI: https://doi.org/10.3949/ccjm.89a.21020
Samantha J. Zwiebel
Assistant Professor of Clinical Psychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Adele C. Viguera
Staff Psychiatrist, Department of Psychiatry, Neurological Institute, Cleveland Clinic, Cleveland, OH; Clinical Assistant Professor of Psychiatry, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Clinical syndromes after discontinuing antidepressants

    ConditionCategoryOnset, durationSymptoms
    Discontinuation syndromeAcute withdrawalOnset 36–96 hours
    Duration < 6 weeks
    New symptoms not present before antidepressant was started or stopped
    ReboundOnset 36–96 hours
    Duration < 6 weeks
    Greater severity of original symptoms
    Persistent withdrawal syndromeOnset 24 hours to 6 weeks
    Duration > 6 weeks
    New symptoms and/or greater severity of original symptoms
    New episodeRelapseOnset < 6 weeks
    Duration variable
    Original symptoms at original severity
    RecurrenceOnset > 6 months
    Duration variable
    Original symptoms at original severity
    • Based on information in reference 9.

    • View popup
    TABLE 2

    Discontinuation symptoms by antidepressant drug class

    SystemSSRIsSNRIsTCAsMAOIsAtypicals
    GeneralFlu-like symptomsFlu-like symptomsFlu-like symptomsFlu-like symptomsFlu-like symptoms
    FatigueFatigueFatigueFatigue
    DiaphoresisFatigue
    CardiovascularTachycardiaTachycardiaTachycardiaTachycardia(Limited data)
    FlushingHypertension, hypotension
    Syncope
    ArrhythmiaArrhythmia
    GastrointestinalNausea, vomitingNausea, vomitingNausea, vomitingNausea, vomitingNausea, vomiting
    DiarrheaDiarrheaDiarrheaDiarrheaDiarrhea
    AnorexiaAnorexiaAnorexiaAnorexiaAnorexia (mirtazapine)
    NeurologicHeadacheHeadacheHeadacheHeadacheHeadache
    Gait instabilityGait instabilityParesthesiasParesthesiasDizziness
    DizzinessDizzinessTremor, ataxiaTremor, ataxiaParesthesias
    Paresthesias, brain zapsParasthesias, brain zapsSeizureSeizure, myoclonus, muscle jerkingTremor
    Tremor, ataxiaTremor, ataxiaParkinsonismDystonia (bupropion)
    Myclonus, muscle jerkingStroke-like symptomsParkinsonism
    ParkinsonismSeizure, myoclonus, muscle jerkingDystonia
    Catatonia
    PsychiatricAnxiety, panicAnxiety, panicAnxiety, panicDepression, labilityAnxiety, panic
    Depression, maniaDepression, maniaDepression, maniaSuicidal ideationDepression, mania
    Suicidal ideationSuicidal ideationSuicidal ideationAnger, irritabilitySuicidal ideation
    Anger, irritabilityAnger, irritabilityAnger, irritabilityAggression, agitationAnger, irritability
    Mood swingsMood swingsMood swingsMood swings
    Depersonalization, derealizationDepersonalization, derealizationDerealizationHallucinationsDepersonalization, derealization
    HallucinationsDelusions
    HallucinationsHallucinationsDelusions
    CognitiveConfusion, deliriumConfusion, deliriumConfusion, deliriumConfusion, delirium(Limited data)
    InattentionInattentionInattentionInattention
    SleepSleep disturbancesSleep disturbancesSleep disturbancesSleep disturbancesSleep disturbances
    Nightmares, vivid dreamsNightmares, vivid dreamsNightmares, vivid dreamsNightmares, vivid dreamsNightmares, vivid dreams
    VisualVision changesVision changesVision changesVision changes(Limited data)
    SexualDysfunctionDysfunctionDysfunctionDysfunctionDysfunction
    • MAOIs = monoamine oxidase inhibitors; SNRIs = serotonin-norepinephrine reuptake inhibitors; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic and tetracyclic antidepressants

    • Based on information in references 6,7,13,14.

    • View popup
    TABLE 3

    Risk factors for antidepressant discontinuation syndrome

    Longer duration of treatment
    Higher dose of drug
    Shorter half-life of drug
    Higher receptor affinity of drug
    Younger patient age
    History of discontinuation symptoms
    Abrupt discontinuation
    High-risk medication (see Table 4)
    • Based on information in references 6,7,14,23,24,26,28–32.

    • View popup
    TABLE 4

    Risk of antidepressant discontinuation syndrome (ADS): A summary of antidepressant dosing

    Risk of ADSName (brand name)Starting daily dose (mg)Daily dose range (mg)Typical dose increment (mg) (conservative dose increment)
    LowBupropion XL (Wellbutrin XL)a150150–450150
    Doxepin (Silenor)33–63
    Fluoxetine (Prozac)a1010–8010
    Levomilnacipran (Savella)2020–12040 (20)
    Milnacipran (Fetzima)2550–30025–50 (12.5)
    Vilazodone (Viibryd)1010–4010
    Citalopram (Celexa)1010–4010
    Escitalopram (Lexapro)55–3010 (5)
    Mirtazapine (Remeron)7.5–157.5–6015 (7.5)
    IntermediateSertraline (Zoloft)2525–30050 (12.5–25)
    Trazodone (Deseryl)25–5025–40050 (25)
    Vortioxetine (Trintellix)55–205
    Amitriptyline (Elavil)10–2510–30050 (10–25)
    Clomipramine (Anafranil)2525–30050 (25)
    Desipramine (Norpramin)2525–30025–50 (10–25)
    Desvenlafaxine (Pristiq)2550–40050 (25)
    Doxepin (Sinequan)2525–30025–50 (10–25)
    Duloxetine DR (Cymbalta DR)20–3030–12030 (20)
    HighFluvoxamine (Luvox)b2525–30050 (12.5–25)
    Imipramine (Tofranil)2525–30025–50 (10–25)
    Nortriptyline (Pamelor)10–5010–15025–50 (10–25)
    Paroxetine (Paxil)a1010–5010 (5)
    Phenelzine (Nardil)157.5–9015
    Tranylcypromine (Parnate)1010–6010
    Venlafaxine ER (Effexor ER)37.575–37537.5
    • ↵a Potent CYP 2D6 inhibitor.

    • ↵b Potent CYP 1A2 inhibitor.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 89 (1)
Cleveland Clinic Journal of Medicine
Vol. 89, Issue 1
1 Jan 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Discontinuing antidepressants: Pearls and pitfalls
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Discontinuing antidepressants: Pearls and pitfalls
Samantha J. Zwiebel, Adele C. Viguera
Cleveland Clinic Journal of Medicine Jan 2022, 89 (1) 18-26; DOI: 10.3949/ccjm.89a.21020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Discontinuing antidepressants: Pearls and pitfalls
Samantha J. Zwiebel, Adele C. Viguera
Cleveland Clinic Journal of Medicine Jan 2022, 89 (1) 18-26; DOI: 10.3949/ccjm.89a.21020
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • SYMPTOMS AND RISK OF ANTIDEPRESSANT DISCONTINUATION
    • DISCONTINUATION SYNDROME VS WITHDRAWAL
    • THE PHARMACOKINETICS BEHIND DISCONTINUATION SYNDROME
    • WHO IS MOST AT RISK OF DISCONTINUATION SYMPTOMS?
    • PREVENTING AND MANAGING DISCONTINUATION SYMPTOMS
    • TAPERING TO CHANGE ANTIDEPRESSANT MEDICATIONS
    • FUTURE DIRECTIONS
    • TAKE-HOME POINTS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • Clinical impact of 2020 American Heart Association statement on menopause and cardiovascular disease risk
  • PubMed
  • Google Scholar

Cited By...

  • Deprescribing antidepressant medications at end-of-life
  • Antidepressant use and hyperactive delirium at the end of life: retrospective study
  • Google Scholar

More in this TOC Section

  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Managing right ventricular failure in the setting of pulmonary embolism
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Drug Therapy
  • Men's Health
  • Mental Health
  • Neurology
  • Preventive Care
  • Women's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire